Relationship between serum and sol secretory leukoprotease inhibitor (SLPI) during exacerbations of chronic bronchitis Source: Eur Respir J 2006; 28: Suppl. 50, 796s Year: 2006
Increased detection of interleukin-;5 in sputum by addition of protease inhibitors Source: Eur Respir J 2001; 18: 685-691 Year: 2001
Levels of proteinase 3 and neutrophil elastase in plasma, BAL and biopsies in COPD Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020
Usefulness of selective neutrophil elastase inhibitor, sivelestat, in ALI patients with SIRS Source: Annual Congress 2012 - How to use technology to provide better critical care Year: 2012
A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: Lung Science Conference 2015 Year: 2015
SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition Source: Eur Respir J 2011; 37: 1083-1090 Year: 2011
Elevation of neutrophil collagenase (MMP-8) and elastase during COPD exacerbation Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD Year: 2008
Bronchial inflammation without asthma symptoms, relation to low neutrophil activity in serum Source: Eur Respir J 2002; 20: Suppl. 38, 143s Year: 2002
Decreased levels of secretory leucoprotease inhibitor in the pseudomonas -infected cystic fibrosis lung are due to neutrophil elastase degradation Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009
Increased levels of human myeloperxidase (MPO) and neutrophil lipocalin (HNL/NGAL) in childhood asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019
A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation Source: Eur Respir J, 53 (6) 1900303; 10.1183/13993003.00303-2019 Year: 2019
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
PP102 – A serum biomarker reflecting human neutrophil elastase degraded calprotectin is elevated in COPD and IPF Source: ERS Lung Science Conference 2021 Year: 2021
LSC Abstract – A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015
Imbalance between leukoprotease inhibitor levels and neutrophils in BAL from smokers with chronic bronchitis and recurrent exacerbations Source: Eur Respir J 2001; 18: Suppl. 33, 66s Year: 2001
Differences in serum levels of inflammatory markers, proteases and antiproteases in COPD patients with and without emphysema Source: Eur Respir J 2007; 30: Suppl. 51, 142s Year: 2007
Matrix metalloproteinase -9 and neutrophil elastase complexed with α 1 - inhibitor proteinase in children with recurrent upper respiratory tract diseases Source: Eur Respir J 2001; 18: Suppl. 33, 181s Year: 2001
Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema Source: Eur Respir J 2002; 19: 1050-1057 Year: 2002
A point of care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019
The influence of the COPD exacerbation treatment on the MMP-9 concentration in serum, induced sputum and BAL Source: Eur Respir J 2005; 26: Suppl. 49, 298s Year: 2005